Head to head
Amgen vs Eli Lilly and Co
Side-by-side on the measures that matter, with a plain-English read. Full detail: AMGN · LLY
AMGN
Amgen
406.60-0.89%
1-year price shape — +47% over the period
Quant Rating B · 72/100
vs
LLY
Eli Lilly and Co
1,148.67-1.84%
1-year price shape — +57% over the period
Quant Rating B · 77/100
Eli Lilly and Co edges it on the scoreable measures. Eli Lilly and Co has the highest Quant Rating (77); Eli Lilly and Co has done best over the past year (+57%); Eli Lilly and Co earns the most per share.
| AMGN | LLY | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Drug Manufacturers - General |
| Last price | 406.60 | 1,148.67 |
| Change today | -0.89% | -1.84% |
| 1-year return | +47.5% | +57.0% |
| Market cap | $219.82B | $1.08T |
| 52-week range | 263.36 – 447.03 | 711.59 – 1,292.65 |
| Valuation | ||
| P/E (TTM) | 25.25 | 38.56 |
| P/E percentile, own 5-yr range | 51st | 5th |
| P/B | 18.81 | 31.92 |
| Dividend yield | 2.41% | 0.56% |
| Profitability & growth | ||
| EPS (TTM) | 14.23 | 22.95 |
| Net profit (TTM) | $7.69B | $21.60B |
| Revenue (TTM) | $38.10B | $79.67B |
| Revenue growth (YoY) | +9.5% | +47.7% |
| Gross margin | 69.5% | 83.4% |
| Operating margin | 30.0% | 49.7% |
| Net margin | 23.0% | 33.5% |
| Free cash flow (TTM) | $10.18B | $13.56B |
| Ownership & sentiment | ||
| Institutional ownership | 84.0% | 79.5% |
| Insider activity (12mo) | 22 buy / 11 sell | 5 buy / 7 sell |
| Short interest (% of float) | 2.4% | 0.8% |
| Analyst consensus | 56% buy / 31% hold / 12% sell (16) | 86% buy / 10% hold / 5% sell (21) |
| Analyst price target | $413 (+2%) | $1,373 (+19%) |
| StockVane view | ||
| StockVane Quant Rating | B (72) | B (77) |
| Company | ||
| Employees | 31,500 | 50,000 |
| Founded | 1980 | 1876 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.